Last reviewed · How we verify
IOCARMIC ACID
IOCARMIC ACID is a iocarmic acid drug. It is currently in Phase 2 development.
Iocarmic acid is thought to work by modulating a specific biological pathway, although the exact mechanism is not well understood.
Iocarmic acid is a small molecule drug of the iocarmic acid class, but limited information is available on its development, approval status, and commercial availability. The original developer and current owner of iocarmic acid are unknown, and its target and approved indications have not been disclosed. As a result, there is no information on its half-life, bioavailability, or generic manufacturers. Iocarmic acid's commercial status, including whether it is patented or off-patent, is also unknown. Further research is needed to understand the pharmacology and clinical utility of this compound.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IOCARMIC ACID |
|---|---|
| Drug class | iocarmic acid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have a complex communication system. Iocarmic acid is believed to interact with this system, influencing how cells talk to each other and respond to signals. This interaction may help to regulate various cellular processes, but more research is needed to fully understand how it works.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IOCARMIC ACID CI brief — competitive landscape report
- IOCARMIC ACID updates RSS · CI watch RSS
Frequently asked questions about IOCARMIC ACID
What is IOCARMIC ACID?
How does IOCARMIC ACID work?
What drug class is IOCARMIC ACID in?
What development phase is IOCARMIC ACID in?
Related
- Drug class: All iocarmic acid drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing